OncoZenge AB

ONCOZ

SE0015504097

Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 16:29:54 23/05/2024 BST			5-day change	1st Jan Change
3.49 ^SEK	-2.92%		-7.79%	+12.94%

05-21	OncoZenge AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-08	Oncozenge AB Appoints Paolo Bossi as Member of the Advisory Board	CI

Certain Ordinary Shares of OncoZenge AB are subject to a Lock-Up Agreement Ending on 5-SEP-2021.

September 04, 2021

Certain Ordinary Shares of OncoZenge AB (publ) are subject to a Lock-Up Agreement Ending on 5-SEP-2021. These Ordinary Shares will be under lockup for 180 days starting from 9-MAR-2021 to 5-SEP-2021.

Details:
All of the company board members and members of the executive management as well as Peter Wolpert has promised not to sell shares for a period of 180 days from the first day of trading.

Latest news about OncoZenge AB

OncoZenge AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-21	CI
Oncozenge AB Appoints Paolo Bossi as Member of the Advisory Board	04-08	CI
OncoZenge Announces Read-Out of Positive Stability Data for BupiZenge	04-04	CI
Oncozenge Explores Strategic Options for Bupizeng in China	03-11	CI
OncoZenge AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-15	CI
OncoZenge Seeks to Expand Patent Protection for Oral Lozenge Product BupiZenge	02-07	MT
OncoZenge AB Files Patent Application for Strengthened IP Protection for BupiZenge	02-07	CI
OncoZenge Seeks Priority Medicines Status for Oral Pain Treatment in Europe	01-02	MT
Oncozenge Announces Formation of Advisory Board with Stephen Sonis and Pooja Nandwani Patel	12-13	CI
Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-Development of BupiZenge in the United States	11-28	CI
Oncozenge AB Confirms the New Formulation of Oncozenge's Drug Candidate Bupizenge?? Is Clean	11-21	CI
OncoZenge AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	31/10/23	CI
Oncozenge AB Appoints Stian Kildal as New CEO	11/09/23	CI
OncoZenge AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	31/08/23	CI
OncoZenge AB Reports Earnings Results for the First Quarter Ended March 31, 2023	16/05/23	CI
OncoZenge AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	14/02/23	CI
OncoZenge AB Reports Earnings Results for the Full Year Ended December 31, 2022	14/02/23	CI
OncoZenge AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	15/11/22	CI
OncoZenge AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	16/08/22	CI
OncoZenge AB Reports Earnings Results for the First Quarter Ended March 31, 2022	17/05/22	CI
Sweden's OncoZenge Starts Dosing in Toxicity Study for Pain Relief Drug Candidate	15/02/22	MT
OncoZenge AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	15/02/22	CI
OncoZenge AB Reports Earnings Results for the Full Year Ended December 31, 2021	15/02/22	CI
OncoZenge AB Initiates Toxicity Study and Announces Modification to the Clinical Plan	15/02/22	CI
Certain Ordinary Shares of OncoZenge AB are subject to a Lock-Up Agreement Ending on 5-SEP-2021.	04/09/21	CI

Chart OncoZenge AB

Duration

Period

More charts

Company Profile

OncoZenge AB is a Sweden-based pharmaceutical company, that develops products for cancer supportive care. OncoZenge's vision is to improve the quality of life for patients with severe oral pain, for example caused by radiotherapy or chemotherapy in the treatment of cancer. The Company works on the introduction of its project BupiZenge. Its strategic and operational work focuses on the development of BupiZenge, which is a formulation of bupivacaine in the form of a lozenge. BupiZenge meets a need for pain relief in the mouth and throat, for example associated with oral mucositis, a serious complication after radiation or other cancer treatment. Preparations for registration establishment clinical studies are ongoing.

Sector

Pharmaceuticals

Calendar

31/05/2024 - Annual General Meeting

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ONCOZENGE AB	+12.94%	3.92M
ELI LILLY AND COMPANY	+38.69%	723B
NOVO NORDISK A/S	+34.28%	595B
JOHNSON & JOHNSON	-4.49%	369B
MERCK & CO., INC.	+20.24%	332B
ABBVIE INC.	+2.12%	282B
ASTRAZENECA PLC	+17.02%	244B
NOVARTIS AG	+9.31%	208B
ROCHE HOLDING AG	-5.07%	205B
PFIZER, INC.	-0.35%	168B

Other Pharmaceuticals

OncoZenge AB

Equities

ONCOZ

SE0015504097

Pharmaceuticals

Certain Ordinary Shares of OncoZenge AB are subject to a Lock-Up Agreement Ending on 5-SEP-2021.

Latest news about OncoZenge AB

Chart OncoZenge AB

Company Profile

Income Statement Evolution

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals